Clinical Trials · NCT00072839

Safety and Efficacy of ALX-0600 in Subjects With Active Crohn's Disease

Name: Safety and Efficacy of ALX-0600 in Subjects With Active Crohn's Disease
Creator: Peptide Science Daily
License: https://clinicaltrials.gov/about-site/terms-conditions

CompletedPhase 2Teduglutide

Phase: Phase 2
Recruitment status: Completed
Sponsor: Shire
Enrollment: 100
Start date: Nov 2003
Locations: 26 sites, United States, Canada
Primary endpoint: The primary efficacy variable is the percentage of subjects who respond to treatment, defined as the percentage of subjects who are in remission (CDAI less than 150) or have a 100-point or greater reduction from baseline in CDAI score at dosing Week 8.

View Teduglutide compound reference